GLP1R and type 2 diabetes mellitus: Further long‐term studies are needed to explore the potential cancer‐preventive effects of GLP‐1 RA‐based therapies and BS—both in OAC and non‐OAC settings—along with the underlying mechanisms for people with and without T2D.